New pill targets genetic driver in advanced cancers
Disease control
Ongoing
This early-stage study is testing a new oral medication called D3S-002 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to find a safe dose, see how the body processes the drug, and look for early signs that it might …
Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC